The Latin America Biobanking Market was valued at $367.8 Million in 2025 and projected to reach to $555.4 Million by 2030, representing a compound annual growth rate of 8.6%. Latin America's biobanking market is positioned for sustained growth driven by increasing healthcare investments and the region's focus on precision medicine development.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America's biobanking market is valued at USD 367.8 million in 2025 and is projected to grow to USD 555.4 million by 2030, with a CAGR of 8.6%, reflecting strong regional momentum in life sciences infrastructure.
Increasing investments in precision medicine across Latin America are driving demand for advanced biobanking solutions, enabling personalized treatment approaches and improving patient outcomes in the region.
Rising prevalence of chronic diseases including diabetes, cardiovascular conditions, and cancer throughout Latin America is accelerating the need for comprehensive biobanking and sample storage capabilities.
Expanding healthcare infrastructure and modernization initiatives across Latin American countries are creating opportunities for biobanking facilities, research centers, and diagnostic laboratories to establish operations.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SOFTWARE (Offering) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.1% from 2025 to 2030 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 7.65 (2025) |
| Revenue Forecast (Billions) | ~USD 11.82 (2030) |
| Segments Covered | Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User |
8 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| MAXCYTE, INC | United States | Public Company | ExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs), |
| HDFC BANK | India | Public Company | Retail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments), |
| STANDARD CHARTERED | United Kingdom | Private Company | Financial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance, |
| YES BANK | India | Public Company | Retail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking, |
| CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED | India | Public Company | Vehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions, |
| AXIS MUTUAL FUND | India | Private Company | Actively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| PHC HOLDINGS CORPORATION | Japan | Public Company | Diabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays, |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment), |
| AVANTOR, INC. | United States | Public Company | Materials and consumables,Equipment and instrumentation,Services and specialty procurements, |
| CRYOPORT | United States | Public Company | Life Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| LABCORP | United States | Public Company | Routine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics, |
| HAIER BIOMEDICAL | China | Public Company | ULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment, |
| HAMILTON COMPANY | United States | Public Investment Firm | Fund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts, |
MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.
HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.
STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.
YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.
CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.
AXIS MUTUAL FUND is a private company based in India that was founded in 2009.
THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.
PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.
QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.
MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.
AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.
CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.
AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.
LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.
EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.
HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.
HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.
| Country | 2025 size (native) |
|---|---|
| Brazil | USD 141.2 Million |
| Mexico | USD 87.7 Million |
| Rest Of Latin America | USD 124.7 Million |
The Latin America biobanking market is valued at USD 367.8 million in 2025 and is projected to reach USD 555.4 million by 2030.
Latin America's biobanking market is growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.
Brazil, Mexico, and Argentina are the primary drivers of biobanking expansion in Latin America, supported by increased pharmaceutical R&D and healthcare infrastructure investment.
Key drivers include rising precision medicine adoption, growing chronic disease prevalence, regulatory harmonization, and increased collaboration between academic and private biobanking institutions across Latin America.
Latin America's 8.6% CAGR is slightly below the global average of 9.1%, reflecting the region's emerging market status but demonstrating strong growth potential in biobanking infrastructure and research capabilities.
This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.
Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.
With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:
Full forecast, segment splits, and company analysis for all Biobanking Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report